

LyFE Lymphoma Forum of Excellence 2025:
What's new in lymphoid neoplasias?
Bellinzona, January 24–26, 2025
DAY 1 – FRIDAY, 24.01.2025

09:45–11.00	Visit to the Institute of Oncology Research (IOR)	A. Rinaldi
11.00–11.45	Key note lecture: T-cell lymphoma biology <i>Transfer to Ospedale San Giovanni</i>	L. De Leval
12:00–13:00	Lunch <i>Chairperson: E. Zucca</i>	
13:30–14:00	Current definition of the most common lymphoma entities	L. Mazzucchelli
14:00–14:30	The immune-microenvironment of lymphomas	A. Tzankov
14:30–15:00	Introduction to basic molecular biology for clinicians	A. Mensah
15:00–15:30	Interpretation of flow of cytometry	G. Stüssi
15:30–16:00	Break <i>Chairperson: F. Cavalli</i>	
16:30–16:50	PET metrics: where do we stand?	L. Ceriani
16:50–17:10	Modern radiotherapy approaches	L. Deantonio
17:10–17:30	DLBCL	A. Davies
17:30–17:50	Aggressive extranodal lymphomas	E. Zucca
17:50–18:30	Discussion of cases of participants	

DAY 2 – SATURDAY, 25.01.2025

	<i>Chairperson: A. Ferreri</i>	
08:40–09:00	Chronic lymphocytic leukemia	D. Rossi or S. Stilgenbauer
09:00–09:20	Waldenström macroglobulinemia	M.C. Piroso
09:20–09:40	Follicular lymphomas	S. Luminari
09:40–10:00	Marginal zone lymphoma	E. Zucca
10:00–10:20	Histological transformation of indolent lymphomas	D. Rossi
10:20–11:00	Break	
11:00–11:20	Hodgkin lymphoma	M.C. Piroso
11:20–11:40	Peripheral T-cell lymphomas	S. Luminari
11:40–12:00	Amyloidosis	B. Gerber
12:00–13:30	Discussion of cases of participants	
13:30–14:40	Lunch <i>Chairperson: S. Luminari</i>	
14:40–15:00	Mantle-cell lymphoma	F. Cavalli
15:00–15:20	Has CNS prophylaxis still a role in DLBCL?	A. Ferreri
15:20–15:40	Cutaneous B- and T-cell lymphoma	H. Beltraminelli
15:40–16:00	CAR-T cells	F. Simonetta
16:00–16:30	Break	
16:30–18:00	Discussion of cases of participants	

DAY 3 – SUNDAY, 26.01.2025

	<i>Chairperson E. Zucca</i>	
09:00–10:00	Discussion of cases of participants	
10:00–10:30	Mechanisms of lymphoma resistance to treatment	F. Bertoni
10:30–11:00	Targeted treatments in lymphoma	A. Stathis
11:00–11:30	Multiple myeloma – First-line therapy	E. Lerch
11:30–12:00	Multiple myeloma – Relapsing/Refractory disease	B. Gerber
	Concluding remarks & End of the meeting	E. Zucca